{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:16:39Z","timestamp":1787242599208,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"8","funder":[{"name":"Netherlands ALS Foundation","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Gold Coast criteria (GCC) have been proposed as a means of selecting patients for amyotrophic lateral sclerosis (ALS) clinical trials. We aimed to characterise disease progression according to the GCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from population-based ALS registries from the Netherlands and Belgium were analysed. The GCC additionally define ALS as lower motor neuron (LMN) dysfunction in \u22652 body regions without upper motor neuron dysfunction. Therefore, the revised El Escorial criteria (rEEC) were supplemented with a \u2018Gold Coast ALS\u2019 category for patients with only LMN dysfunction in \u22652 body regions. We assessed survival time, ALS Functional Rating Scale (ALSFRS-R) progression rates and between-patient variability per diagnostic category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 5957 ALS patients, of whom 600 (10.1%) fulfilled the GCC but not the rEEC, and 95 (1.6%) fulfilled only the rEEC. ALSFRS-R progression rates were similar for the rEEC (0.84 points\/month) and GCC (0.81 points\/month) with similar variability (standard deviation of 0.59 vs. 0.60) and median survival time (17.8 vs.18.7 months). Survival time and average progression rates varied (p&lt;0.001) between categories. Per category, however, there was considerable between-patient variability with progression rates ranging from: \u22122.10 to \u22120.14 (definite), \u22121.94 to \u22120.06 (probable), \u22122.10 to \u22120.02 (probable laboratory supported), \u22121.79 to \u22120.02 (possible) and \u22121.31 to 0.08 (Gold Coast).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The GCC broaden the definition of ALS, allowing more patients to participate in trials, while minimally impacting population heterogeneity. Given the large variability per diagnostic category, selecting only specific categories for trials may not result in a more homogeneous study population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2022-328823","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:25:47Z","timestamp":1654176347000},"page":"865-870","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Characterising ALS disease progression according to El Escorial and Gold Coast criteria"],"prefix":"10.1136","volume":"93","clinical-trial-number":[{"clinical-trial-number":"nct03626012","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-3397","authenticated-orcid":false,"given":"Adriaan D","family":"de Jongh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Masrori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5572-9657","authenticated-orcid":false,"given":"Jan H","family":"Veldink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-2357","authenticated-orcid":false,"given":"Philip","family":"van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-5967","authenticated-orcid":false,"given":"Ruben P A","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2023052203450714000_93.8.865.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31287-4"},{"key":"2023052203450714000_93.8.865.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70129-2"},{"key":"2023052203450714000_93.8.865.3","doi-asserted-by":"publisher","DOI":"10.1080\/146608200300079536"},{"key":"2023052203450714000_93.8.865.4","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1212\/WNL.0000000000006855","article-title":"Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials","volume":"92","author":"van Eijk","year":"2019","journal-title":"Neurology"},{"key":"2023052203450714000_93.8.865.5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clinph.2018.11.021","article-title":"Diagnostic criteria for amyotrophic lateral sclerosis: a multicentre study of inter-rater variation and sensitivity","volume":"130","author":"Johnsen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"2023052203450714000_93.8.865.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2007.09.143"},{"key":"2023052203450714000_93.8.865.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2020.04.005"},{"key":"2023052203450714000_93.8.865.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17670-8"},{"key":"2023052203450714000_93.8.865.9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ana.26045","article-title":"Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis","volume":"89","author":"Hannaford","year":"2021","journal-title":"Ann Neurol"},{"key":"2023052203450714000_93.8.865.10","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-021-00253-2","article-title":"The gold coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population","volume":"10","author":"Shen","year":"2021","journal-title":"Transl Neurodegener"},{"key":"2023052203450714000_93.8.865.11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/mus.27392","article-title":"Gold coast diagnostic criteria: implications for ALS diagnosis and clinical trial enrollment","volume":"64","author":"Vucic","year":"2021","journal-title":"Muscle Nerve"},{"key":"2023052203450714000_93.8.865.12","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1016\/j.clinph.2021.08.014","article-title":"Gold coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis","volume":"132","author":"Pugdahl","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"2023052203450714000_93.8.865.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2011.244939"},{"key":"2023052203450714000_93.8.865.14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011467"},{"key":"2023052203450714000_93.8.865.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322541"},{"key":"2023052203450714000_93.8.865.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00210-5"},{"key":"2023052203450714000_93.8.865.17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/21678421.2019.1634736","article-title":"Implications of spirometric reference values for amyotrophic lateral sclerosis","volume":"20","author":"van Eijk","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023052203450714000_93.8.865.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30089-9"},{"key":"2023052203450714000_93.8.865.19","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000194316.91908.8a"},{"key":"2023052203450714000_93.8.865.20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/WNL.0000000000012545","article-title":"Innovating clinical trials for amyotrophic lateral sclerosis","volume":"97","author":"van Eijk","year":"2021","journal-title":"Neurology"},{"key":"2023052203450714000_93.8.865.21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100410"},{"key":"2023052203450714000_93.8.865.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"2023052203450714000_93.8.865.23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/21678421.2019.1666875","article-title":"The revised El Escorial criteria \"clinically probable laboratory supported ALS\"-once a promising now a superfluous category?","volume":"21","author":"Braun","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023052203450714000_93.8.865.24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/21678421.2019.1599955","article-title":"Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis","volume":"20","author":"Palumbo","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023052203450714000_93.8.865.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"2023052203450714000_93.8.865.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916945"},{"key":"2023052203450714000_93.8.865.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678421.2019.1675710","article-title":"In pursuit of the normal progressor: the Holy Grail for ALS clinical trial design?","volume":"21","author":"van Eijk","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023052203450714000_93.8.865.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-015-2343-6"},{"key":"2023052203450714000_93.8.865.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3501"},{"key":"2023052203450714000_93.8.865.30","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1212\/WNL.0000000000004038","article-title":"Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease","volume":"88","author":"Rooney","year":"2017","journal-title":"Neurology"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-328823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T06:51:05Z","timestamp":1684738265000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-328823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,7,14]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/jnnp-2022-328823"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-328823","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}